相关实验视频

Updated: Sep 14, 2025

A Murine Model of Vertical Sleeve Gastrectomy
06:47

A Murine Model of Vertical Sleeve Gastrectomy

Published on: December 18, 2017

11.2K

袖子到旁路转换与袖子与辅助GLP-1受体激动剂:一个学术多中心的回顾性研究

Avery Brown1,2, Helena Sergent3, Alexander Hien Vu4

  • 1Department of General Surgery, Bellevue Hospital, 462 1St Ave, New York, NY, 10016, USA. avery.brown@nyulangone.org.

Surgical endoscopy
|July 21, 2025
PubMed
概括

对于在袖子胃切除术后体重减轻不足的患者,转换为Roux-En-Y胃绕道 (cRYGB) 提供了比葡萄糖类-1受体激动剂 (GLP1-RAs) 更大的长期体重减轻. 与cRYGB相比,GLP1-RAs在HbA1c控制中没有显著差异.

关键词:
转换性减肥手术是什么意思在 GLP1 中,GLP1 是 GLP1 的代名词.鲁克斯-en-y的胃绕道术塞马格卢提德 (semaglutide) 是一种类型的袖子胃切除术是什么意思提尔泽帕提德是什么药物

更多相关视频

Single-Anastomosis Duodeno-Ileal Bypass with Sleeve Gastrectomy Model in Mice06:40

Single-Anastomosis Duodeno-Ileal Bypass with Sleeve Gastrectomy Model in Mice

Published on: February 10, 2023

1.6K
Sleeve Gastrectomy in Mice using Surgical Clips05:16

Sleeve Gastrectomy in Mice using Surgical Clips

Published on: November 14, 2020

6.8K

相关概念视频

Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
421
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
305
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
263
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
262
Oral Hypoglycemic Agents: Sulfonylureas01:17

Oral Hypoglycemic Agents: Sulfonylureas

Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
342
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
265